TNXP_OUT_1 [2025-03-24 09:09:05 -0400] 2159 Bytes | 566 tokens | Cum: 566 tkns (7.07% of 8k)
==========================================================================

Listen up, partner—it's 9:09:04 AM on Mon Mar 24, 2025 -0400, and I’m revved up about Tonix Pharmaceuticals (TNXP), climbing from 23.03 to 29.1. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Tonix Pharmaceuticals:

C1 - Today 08:00AM - Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
C2 - Mar-20-25 07:00AM - As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
C3 - Mar-18-25 04:30PM - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
C4 - Mar-14-25 08:35AM - Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
C5 - Mar-13-25 07:00AM - Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
C6 - Mar-12-25 01:12PM - Life Sciences Investor Forum Agenda Announced for March 13th
C7 - Mar-12-25 01:12PM 07:30AM - Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
C8 - Mar-11-25 07:00AM - Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Tonix Pharmaceuticals (TNXP)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TNXP_OUT_3 [2025-03-24 09:09:08 -0400] 1039 Bytes | 310 tokens | Cum: 878 tkns (10.97% of 8k)
==========================================================================

Showing C1 (chunk 1 of 16): C1:
**Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia**
Date: Today 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/24/3047773/28908/en/Tonix-Pharmaceuticals-Announces-that-FDA-Will-Not-Require-an-Advisory-Committee-Meeting-to-Discuss-New-Drug-Application-for-TNX-102-SL-for-the-Management-of-Fibromyalgia.html

March 24, 2025 08:00 ET| Source:Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals Holding Corp.

TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years

Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025

CHATHAM, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasd

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_5 [2025-03-24 09:09:15 -0400] 1047 Bytes | 250 tokens | Cum: 1130 tkns (14.12% of 8k)
==========================================================================

Showing C1 (chunk 2 of 16): aq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Company’s New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia. If approved, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) would be the first new treatment option for fibromyalgia patients in 15 years.

“We are pleased that FDA will not require an advisory committee meeting as part of the regulatory review process for TNX-102 SL,” said Seth Lederman, M.D., President, and Chief Executive Officer of Tonix Pharmaceuticals. “We believe that TNX-102 SL has the potential to be the first member of a new class of medicines for the management of fibromyalgia, a debilitating condition affecting over 10

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_7 [2025-03-24 09:09:16 -0400] 1039 Bytes | 295 tokens | Cum: 1539 tkns (19.24% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T12:06:16Z - Tonix Pharma (TNXP) Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New...
A2 - 2025-03-24T12:03:08Z - Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss N...
A3 - 2025-03-21T17:05:38Z - 12 Health Care Stocks Moving In Friday's Intraday Session - GlucoTrack (NASDAQ:GCTK), CervoMed (NASD...
A4 - 2025-03-20T14:20:05Z - InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Single-Dose Vaccine...
A5 - 2025-03-20T11:07:12Z - As Mpox Cases Spread Around The World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potent...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TNXP_OUT_9 [2025-03-24 09:09:18 -0400] 1039 Bytes | 300 tokens | Cum: 1841 tkns (23.01% of 8k)
==========================================================================

Showing A1 (chunk 1 of 15): A1:
**Tonix Pharma (TNXP) Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL**Date: 2025-03-24Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/Corporate+News/Tonix+Pharma+%28TNXP%29+Announces+that+FDA+Will+Not+Require+an+Advisory+Committee+Meeting+to+Discuss+New+Drug+Application+for+TNX-102+SL/24537236.htmlTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) today announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Company's New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia. If approved, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) would be the first new treatment option for fibromyalgia patients in 15 years.

"We are pleased that FDA will not require an ad

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_11 [2025-03-24 09:09:19 -0400] 1039 Bytes | 243 tokens | Cum: 2086 tkns (26.07% of 8k)
==========================================================================

Showing A1 (chunk 2 of 15): visory committee meeting as part of the regulatory review process for TNX-102 SL," said Seth Lederman, M.D., President, and Chief Executive Officer of Tonix Pharmaceuticals. "We believe that TNX-102 SL has the potential to be the first member of a new class of medicines for the management of fibromyalgia, a debilitating condition affecting over 10 million adults in the U.S. We believe we are well positioned to launch TNX-102 SL for the management of fibromyalgia in the fourth quarter of 2025 if approved by the FDA."

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need.

About Fibromyalgia

Fibromyalgia is a common chronic pain disorder that is understood to result from amplified sensory and pain signaling w

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_13 [2025-03-24 09:09:21 -0400] 986 Bytes | 298 tokens | Cum: 2386 tkns (29.83% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-11T11:00:00Z - Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
B2 - 2025-03-03T18:00:00Z - Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight
B3 - 2025-02-05T12:00:00Z - Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
B4 - 2024-11-26T12:00:00Z - Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference
B5 - 2024-11-01T11:00:00Z - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
B6 - 2024-10-29T12:00:00Z - Tonix Pharmaceuticals to Present at BIO-Europe® 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TNXP_OUT_15 [2025-03-24 09:09:25 -0400] 719 Bytes | 186 tokens | Cum: 2574 tkns (32.17% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/11/3040395/28908/en/Tonix-Pharmaceuticals-to-Present-at-the-Zacks-SCR-Life-Sciences-Virtual-Investor-Forum-on-March-13th.htmlTonix Pharmaceuticals, a biopharmaceutical company, announced that its CEO will present at the Zacks SCR Life Sciences Virtual Investor Forum. The company's pipeline includes drug candidates for pain management, vaccines, and other therapeutic areas.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_17 [2025-03-24 09:09:27 -0400] 1019 Bytes | 263 tokens | Cum: 2882 tkns (36.02% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-24 8-K Item 7.01 Regulation FD Disclosure. On March 24, 2025, Tonix Pharmaceuticals Holding Corp. (the Company) announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Companys New Drug Application (NDA) for its TNX-102 SL...

S2 - 2025-03-18 10-K ITEM 7 MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

This Mgts Discussion and Analysis of Fin Cond and Results of Oper includes a number of forward-looking statements that reflect Mgts current views with res...

S3 - 2025-03-18 10-K ITEM 7 MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

This Mgts Discussion and Analysis of Fin Cond and Results of Oper includes a number of forward-looking statements that reflect Mgts current views with res...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TNXP_OUT_19 [2025-03-24 09:09:28 -0400] 1038 Bytes | 240 tokens | Cum: 3124 tkns (39.05% of 8k)
==========================================================================

Showing S1 (chunk 1 of 4): S1:
Item 7.01 Regulation FD Disclosure. On March 24, 2025, Tonix Pharmaceuticals Holding Corp. (the Company) announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Companys New Drug Application (NDA) for its TNX-102 SL product candidate for the management of fibromyalgia. A copy of the press release that discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

The Company updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.02 hereto and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Ex

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_21 [2025-03-24 09:09:30 -0400] 1038 Bytes | 246 tokens | Cum: 3372 tkns (42.15% of 8k)
==========================================================================

Showing S1 (chunk 2 of 4): hibits 99.01 and 99.02 attached hereto, shall not be deemed filed for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01

On March 24, 2025, the Company announced that the FDA will not require an Advisory Committee meeting to discuss the NDA for TNX-102 SL for the management of fibromyalgia.

Forward- Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_23 [2025-03-24 09:09:31 -0400] 1038 Bytes | 196 tokens | Cum: 3570 tkns (44.62% of 8k)
==========================================================================

Showing S1 (chunk 3 of 4): , including those relating to the Companys product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and managements current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, expect, anticipate, intend, plan, believe, estimate, potential, predict, project, should, would and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

TNXP_OUT_25 [2025-03-24 09:09:47 -0400] 4297 Bytes | 1222 tokens | Cum: 4794 tkns (59.92% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+---------------------+-----------------------+-----------------------+-------------------------+
| Volume: 3,486,269 | SMA50: 22.49% | Market Cap: 148.20M | Option/Short: No / No | Sales past 5Y: 5.99% | Sales Surprise: -19.31% |
+-------------------+-----------------------+---------------------+-----------------------+-----------------------+-------------------------+
| Avg Volume: 1.54M | SMA200: -45.11% | Shs Outstand: 4.39M | Short Float: - | Employees: 81 | EPS Surprise: 47.19% |
+-------------------+-----------------------+---------------------+-----------------------+-----------------------+-------------------------+
| Rel Volume: 2.30 | Perf Week: 53.53% | Shs Float: - | Short Ratio: 0.36 | Debt/Eq: 0.06 | P/E: - |
+-------------------+-----------------------+---------------------+-----------------------+-----------------------+-------------------------+
| RSI (14): 63.96 | Perf Month: 138.16% | Inst Own: 2.86% | Short Interest: 0.55M | Sales Y/Y TTM: 29.94% | Earnings: Mar 18 AMC |
+-------------------+-----------------------+---------------------+-----------------------+-----------------------+-------------------------+
| ATR (14): 3.36 | Perf Quarter: -31.03% | Insider Own: 0.00% | Beta: 1.32 | ROE: -106.12% | |
+-------------------+-----------------------+---------------------+-----------------------+-----------------------+-------------------------+
| SMA20: 78.02% | Index: - | Insider Trans: - | Sales Q/Q: -31.68% | ROI: -89.94% | |
+-------------------+-----------------------+---------------------+-----------------------+-----------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: Tonix Pharmaceuticals Holding Corp.
Market Cap: 148195309.43
Shares Outstanding: 6434881
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 10094000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -130036000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 23.03
Average Volume: 1923378.3
30-Day High: 23.03
30-Day Low: 7.38

[Detailed Financials: TTM 2024]
- Total Assets: $162,890,000.0
- Total Liabilities: $23,332,000.0
- Total Equity: $139,558,000.0
- Current Assets: $119,002,000.0
- Current Liabilities: $18,307,000.0

[Income Statement: TTM 2024]
- Revenue: $10,094,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -176.6

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $73,831,000.0

[Detailed Financials: FY 2024]
- Total Assets: $162,890,000.0
- Total Liabilities: $23,332,000.0
- Total Equity: $139,558,000.0
- Current Assets: $119,002,000.0
- Current Liabilities: $18,307,000.0

[Income Statement: FY 2024]
- Revenue: $10,094,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -176.6

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $73,831,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TNXP_OUT_27 [2025-03-24 09:09:51 -0400] 676 Bytes | 167 tokens | Cum: 5243 tkns (65.54% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TNXP_IN_29 [2025-03-24 09:09:52 -0400] 126 Bytes | 29 tokens | Cum: 5332 tkns (66.65% of 8k)
==========================================================================

====================================
[2025-03-24 06:09:52] # Analysis Completed
Elapsed Time: 48.56 seconds